Cargando…
Heterogeneity of paclitaxel distribution in different tumor models assessed by MALDI mass spectrometry imaging
The penetration of anticancer drugs in solid tumors is important to ensure the therapeutic effect, so methods are needed to understand drug distribution in different parts of the tumor. Mass spectrometry imaging (MSI) has great potential in this field to visualize drug distribution in organs and tum...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5175283/ https://www.ncbi.nlm.nih.gov/pubmed/28000726 http://dx.doi.org/10.1038/srep39284 |
_version_ | 1782484631083286528 |
---|---|
author | Giordano, Silvia Zucchetti, Massimo Decio, Alessandra Cesca, Marta Fuso Nerini, Ilaria Maiezza, Marika Ferrari, Mariella Licandro, Simonetta Andrea Frapolli, Roberta Giavazzi, Raffaella Maurizio, D’Incalci Davoli, Enrico Morosi, Lavinia |
author_facet | Giordano, Silvia Zucchetti, Massimo Decio, Alessandra Cesca, Marta Fuso Nerini, Ilaria Maiezza, Marika Ferrari, Mariella Licandro, Simonetta Andrea Frapolli, Roberta Giavazzi, Raffaella Maurizio, D’Incalci Davoli, Enrico Morosi, Lavinia |
author_sort | Giordano, Silvia |
collection | PubMed |
description | The penetration of anticancer drugs in solid tumors is important to ensure the therapeutic effect, so methods are needed to understand drug distribution in different parts of the tumor. Mass spectrometry imaging (MSI) has great potential in this field to visualize drug distribution in organs and tumor tissues with good spatial resolution and superior specificity. We present an accurate and reproducible imaging method to investigate the variation of drug distribution in different parts of solid tumors. The method was applied to study the distribution of paclitaxel in three ovarian cancer models with different histopathological characteristics and in colon cancer (HCT116), breast cancer (MDA-MB-231) and malignant pleural mesothelioma (MPM487). The heterogeneous drug penetration in the tumors is evident from the MALDI imaging results and from the images analysis. The differences between the various models do not always relate to significant changes in drug content in tumor homogenate examined by classical HPLC analysis. The specificity of the method clarifies the heterogeneity of the drug distribution that is analyzed from a quantitative point of view too, highlighting how marked are the variations of paclitaxel amounts in different part of solid tumors. |
format | Online Article Text |
id | pubmed-5175283 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-51752832016-12-29 Heterogeneity of paclitaxel distribution in different tumor models assessed by MALDI mass spectrometry imaging Giordano, Silvia Zucchetti, Massimo Decio, Alessandra Cesca, Marta Fuso Nerini, Ilaria Maiezza, Marika Ferrari, Mariella Licandro, Simonetta Andrea Frapolli, Roberta Giavazzi, Raffaella Maurizio, D’Incalci Davoli, Enrico Morosi, Lavinia Sci Rep Article The penetration of anticancer drugs in solid tumors is important to ensure the therapeutic effect, so methods are needed to understand drug distribution in different parts of the tumor. Mass spectrometry imaging (MSI) has great potential in this field to visualize drug distribution in organs and tumor tissues with good spatial resolution and superior specificity. We present an accurate and reproducible imaging method to investigate the variation of drug distribution in different parts of solid tumors. The method was applied to study the distribution of paclitaxel in three ovarian cancer models with different histopathological characteristics and in colon cancer (HCT116), breast cancer (MDA-MB-231) and malignant pleural mesothelioma (MPM487). The heterogeneous drug penetration in the tumors is evident from the MALDI imaging results and from the images analysis. The differences between the various models do not always relate to significant changes in drug content in tumor homogenate examined by classical HPLC analysis. The specificity of the method clarifies the heterogeneity of the drug distribution that is analyzed from a quantitative point of view too, highlighting how marked are the variations of paclitaxel amounts in different part of solid tumors. Nature Publishing Group 2016-12-21 /pmc/articles/PMC5175283/ /pubmed/28000726 http://dx.doi.org/10.1038/srep39284 Text en Copyright © 2016, The Author(s) http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ |
spellingShingle | Article Giordano, Silvia Zucchetti, Massimo Decio, Alessandra Cesca, Marta Fuso Nerini, Ilaria Maiezza, Marika Ferrari, Mariella Licandro, Simonetta Andrea Frapolli, Roberta Giavazzi, Raffaella Maurizio, D’Incalci Davoli, Enrico Morosi, Lavinia Heterogeneity of paclitaxel distribution in different tumor models assessed by MALDI mass spectrometry imaging |
title | Heterogeneity of paclitaxel distribution in different tumor models assessed by MALDI mass spectrometry imaging |
title_full | Heterogeneity of paclitaxel distribution in different tumor models assessed by MALDI mass spectrometry imaging |
title_fullStr | Heterogeneity of paclitaxel distribution in different tumor models assessed by MALDI mass spectrometry imaging |
title_full_unstemmed | Heterogeneity of paclitaxel distribution in different tumor models assessed by MALDI mass spectrometry imaging |
title_short | Heterogeneity of paclitaxel distribution in different tumor models assessed by MALDI mass spectrometry imaging |
title_sort | heterogeneity of paclitaxel distribution in different tumor models assessed by maldi mass spectrometry imaging |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5175283/ https://www.ncbi.nlm.nih.gov/pubmed/28000726 http://dx.doi.org/10.1038/srep39284 |
work_keys_str_mv | AT giordanosilvia heterogeneityofpaclitaxeldistributionindifferenttumormodelsassessedbymaldimassspectrometryimaging AT zucchettimassimo heterogeneityofpaclitaxeldistributionindifferenttumormodelsassessedbymaldimassspectrometryimaging AT decioalessandra heterogeneityofpaclitaxeldistributionindifferenttumormodelsassessedbymaldimassspectrometryimaging AT cescamarta heterogeneityofpaclitaxeldistributionindifferenttumormodelsassessedbymaldimassspectrometryimaging AT fusoneriniilaria heterogeneityofpaclitaxeldistributionindifferenttumormodelsassessedbymaldimassspectrometryimaging AT maiezzamarika heterogeneityofpaclitaxeldistributionindifferenttumormodelsassessedbymaldimassspectrometryimaging AT ferrarimariella heterogeneityofpaclitaxeldistributionindifferenttumormodelsassessedbymaldimassspectrometryimaging AT licandrosimonettaandrea heterogeneityofpaclitaxeldistributionindifferenttumormodelsassessedbymaldimassspectrometryimaging AT frapolliroberta heterogeneityofpaclitaxeldistributionindifferenttumormodelsassessedbymaldimassspectrometryimaging AT giavazziraffaella heterogeneityofpaclitaxeldistributionindifferenttumormodelsassessedbymaldimassspectrometryimaging AT mauriziodincalci heterogeneityofpaclitaxeldistributionindifferenttumormodelsassessedbymaldimassspectrometryimaging AT davolienrico heterogeneityofpaclitaxeldistributionindifferenttumormodelsassessedbymaldimassspectrometryimaging AT morosilavinia heterogeneityofpaclitaxeldistributionindifferenttumormodelsassessedbymaldimassspectrometryimaging |